Selective A1-Antagonists for Treatment of Cognitive Deficits
- 1 July 1991
- journal article
- research article
- Published by Taylor & Francis in Nucleosides and Nucleotides
- Vol. 10 (5) , 1067-1076
- https://doi.org/10.1080/07328319108047244
Abstract
A novel compound, KFM 19, is introduced, which turned out to be a selective adenosine A1-antagonist with good bioavailability. Its pharmacological profile suggests a high therapeutic potential for dementia and related cognitive deficits.Keywords
This publication has 9 references indexed in Scilit:
- Solubilities of Adenosine Antagonists Determined by Radioreceptor AssayJournal of Pharmacy and Pharmacology, 1989
- How does adenosine inhibit transmitter release?Trends in Pharmacological Sciences, 1988
- Simple and rapid measurement of acetylcholine and choline by HPLC and enzymatic-electrochemical detectionNeurochemistry International, 1986
- Effects of caffeine on hippocampal pyramidal cells in vitroBritish Journal of Pharmacology, 1985
- Learning and memory deficits after lesions of the nucleus basalis magnocellularis: Reversal by physostigmineNeuroscience, 1985
- 1,3-Dialkyl-8-(p-sulfophenyl)xanthines: potent water-soluble antagonists for A1- and A2-adenosine receptorsJournal of Medicinal Chemistry, 1985
- [3H]N6-(L-Phenylisopropyl) adenosine binding in brains from young and old ratsNeurobiology of Aging, 1984
- Recruiting responses observed during wakefulness and sleep in unanesthetized chronic catsElectroencephalography and Clinical Neurophysiology, 1964
- New Tables for Multiple Comparisons with a ControlPublished by JSTOR ,1964